Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Classical hematology 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Fanconi Anemia 1

Interventions

pembrolizumab 11Cyclophosphamide 8Gemcitabine 7Cisplatin 7tislelizumab 5Docetaxel 5Nivolumab 4Injections 4spartalizumab 3regorafenib 3Trastuzumab 3Oncolytic Virotherapy 3Irinotecan 3Filgrastim 3Drug Therapy 3Doxorubicin 3Carboplatin 3Bortezomib 3tazemetostat 2pazopanib 2liposomal doxorubicin 2ganitumab 2conatumumab 2belinostat 2Temozolomide 2Taxes 2Tamoxifen 2Sorafenib 2Riluzole 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × SRA737 × Thoracic × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡